Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 38 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
53 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
O CARE PHARMA from Hasselt, company number BE0732714046, closed financial year 2025 with a result of € -47,460 after tax. For that financial year O CARE PHARMA recorded a gross margin of € 48,454 and equity of € -86,406. Compared with financial year 2024, the result moved from € -5,418 to € -47,460. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 19, 2026.
€ -86,406
▼ € 47,460 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -47,460
▼ 776 % more loss than in 2024
Profit after tax over the fiscal year.
€ 34,477
▼ 27% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -106,406.
People and assets in 2025
€ 83,020
▲ 32% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 131,518
▼ 10% vs 2024
€ 30,495 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 26,888
▲ 50% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 16,432
▲ 248% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -7,533 | € -5,648 | € 71,416 | € 48,454 | ▼ 32% |
| Profit after taxes | € -11,486 | € -23,197 | € -5,418 | € -47,460 | ▼ € 42,042 |
| Equity | € -10,331 | € -33,529 | € -38,946 | € -86,406 | ▼ € 47,460 |
| Total debts | € 103,054 | € 94,989 | € 228,785 | € 234,153 | ▲ 2% |
| Cash | € 75,148 | € 4,876 | € 47,354 | € 34,477 | ▼ 27% |
| Retained profit | € -30,331 | € -53,529 | € -58,946 | € -106,406 | ▼ € 47,460 |
| Bank debt | € 75,000 | € 60,987 | € 146,502 | € 131,518 | ▼ 10% |
| Balance sheet total | € 92,722 | € 61,461 | € 189,838 | € 147,746 | ▼ 22% |
Key figures of O CARE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to O CARE PHARMA?
What happened at O CARE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 47,460. Source: NBB ↗
- New establishment in Hasselt. KBO
- Start of the company according to the CBE. KBO
In short
From € 11,486 loss in 2022 to € 47,460 loss in 2025.
Paid € 142 in corporate taxes since 2022.
A new publication or filing at O CARE PHARMA? We notify you, reason included.
Follow O CARE PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind O CARE PHARMA are Annemie Knops and Peter Voortmans.
Directors
According to the 2025 annual accounts
Annemie Knops
Director
Peter Voortmans
Director
Establishments
Establishment units
Physical locations of this company
Hendrik van Veldekesingel 150 box 65
3500 Hasselt
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 53 companies are registered at this address.
All companies at this address →PUTZEYS
€ 83,987 gross margin · 2025
TRUCA
€ 47,248 gross margin · 2025
Exipnos
€ -29,360 gross margin · 2022
Nationale Belgische Taekwon-do Unie
ALLANTA
€ 1.8 million revenue · 2025
+48 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0732.714.046
- VAT number
- BE 0732.714.046
- Registered office
- Hendrik van Veldekesingel 150 bus 65, 3500 Hasselt
- Names & denominations
- O CARE PHARMA · OCP
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 20 August 2019
- Peppol
- Active · Active since 3 Mar 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen